Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies : A Danish population-based cohort study. / Lund, Lars Christian; Rahbek, Martin Torp; Brown, Peter; Obel, Niels; Hallas, Jesper; Frederiksen, Henrik.
I: European Journal of Haematology, Bind 111, Nr. 6, 2023, s. 946-950.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies
T2 - A Danish population-based cohort study
AU - Lund, Lars Christian
AU - Rahbek, Martin Torp
AU - Brown, Peter
AU - Obel, Niels
AU - Hallas, Jesper
AU - Frederiksen, Henrik
N1 - Publisher Copyright: © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - Objectives: We aimed to quantify the risk of death following a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals with haematological malignancies, stratified by virus variants and type of malignancy. Methods: Using the Danish nationwide registries, we conducted a population-based cohort study among individuals who received a discharge diagnosis of haematological malignancies during the 5 years prior to testing positive for SARS-CoV-2 (February 2020–April 2023). All individuals were followed for 30 days after a positive test, and overall and time-stratified case fatality risks (CFR) were estimated. Results: We identified 7154 individuals with a history of haematological malignancies who tested positive for SARS-CoV-2. Among these, we observed 223 deaths, yielding a CFR of 3.1%. The CFR was highest at the beginning of the pandemic (10%) and gradually declined to 1.9% during the period of Omicron BA1/BA2 predominance. The highest CFR was observed among individuals with acute leukaemia (CFR 6.2%, adjusted relative risk 1.95, 95% confidence interval 1.33–2.88) compared to individuals with lymphoma (CFR 3%). Conclusions: We observed a reduction in the CFR over time, which may be attributed to new treatments, COVID-19 vaccination and the emergence of less aggressive variants.
AB - Objectives: We aimed to quantify the risk of death following a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals with haematological malignancies, stratified by virus variants and type of malignancy. Methods: Using the Danish nationwide registries, we conducted a population-based cohort study among individuals who received a discharge diagnosis of haematological malignancies during the 5 years prior to testing positive for SARS-CoV-2 (February 2020–April 2023). All individuals were followed for 30 days after a positive test, and overall and time-stratified case fatality risks (CFR) were estimated. Results: We identified 7154 individuals with a history of haematological malignancies who tested positive for SARS-CoV-2. Among these, we observed 223 deaths, yielding a CFR of 3.1%. The CFR was highest at the beginning of the pandemic (10%) and gradually declined to 1.9% during the period of Omicron BA1/BA2 predominance. The highest CFR was observed among individuals with acute leukaemia (CFR 6.2%, adjusted relative risk 1.95, 95% confidence interval 1.33–2.88) compared to individuals with lymphoma (CFR 3%). Conclusions: We observed a reduction in the CFR over time, which may be attributed to new treatments, COVID-19 vaccination and the emergence of less aggressive variants.
KW - COVID-19
KW - hematologic neoplasms
KW - mortality
U2 - 10.1111/ejh.14108
DO - 10.1111/ejh.14108
M3 - Journal article
C2 - 37740535
AN - SCOPUS:85171896255
VL - 111
SP - 946
EP - 950
JO - Scandinavian Journal of Haematology
JF - Scandinavian Journal of Haematology
SN - 0902-4441
IS - 6
ER -
ID: 395872653